THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Raid Aljumaily to Dose-Response Relationship, Drug

Back to Details
This is a "connection" page, showing publications Raid Aljumaily has written about Dose-Response Relationship, Drug.
Raid Aljumaily
Connection Strength
0.178
Dose-Response Relationship, Drug
  1. Personalized Dosing Versus Fixed Dosing of Immune Checkpoint Inhibitors: A Cost Analysis Study. Am J Ther. 2018 Nov/Dec; 25(6):e767-e768.
    View in: PubMed
    Score: 0.139
  2. Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). Invest New Drugs. 2021 02; 39(1):182-192.
    View in: PubMed
    Score: 0.039
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES